Thus, we included AML patients who were enrolled in NCT02185261 and NCT02027064 and aimed to assess the long-term efficacy of preemptive IFN-α therapy in AML patients following allo-HSCT. This evidence concerns the gene IFNA2 and acute myeloid leukemia.